WBR0401: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Sergekorjian (talk | contribs)
CMEUser, Bots, Bureaucrats, bureaucrats, editnews, interwiki, nocaptcha, nukepages, oversight, smwadministrator, Administrators, Widget editors
5,932 edits
No edit summary
Sergekorjian (talk | contribs)
CMEUser, Bots, Bureaucrats, bureaucrats, editnews, interwiki, nocaptcha, nukepages, oversight, smwadministrator, Administrators, Widget editors
5,932 edits
No edit summary
Line 24: Line 24:
|Explanation=[[File:WBR401.png|center|1000px]]
|Explanation=[[File:WBR401.png|center|1000px]]
|AnswerA=Sotalol
|AnswerA=Sotalol
|AnswerAExp=Sotalol is a potasium channel blocker
|AnswerB=Procainamide
|AnswerB=Metoprolol
|AnswerC=Propafenone
|AnswerBExp=Metoprolol is a beta-blocker (class II) anti-arrhythmic.
|AnswerD=Metoprolol
|AnswerC=Lidocaine
|AnswerCExp=Lidocaine is a sodium channel blocker, which is a class IA anti-arrhythmic.
|AnswerD=Verapamil
|AnswerDExp=Verapamil is a calcium channel blocker, which is a class IV anti-arrhythmic.
|AnswerE=Mexiletine
|AnswerE=Mexiletine
|AnswerEExp=Mexiletine is a sodium channel blocker, which belongs to the class IB anti-arrhythmic drugs.
|EducationalObjectives=Sotalol is a potasium channel blocker (class III) anti-arrhythmic.
|References=Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62(1):9-33.
|References=Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62(1):9-33.
|RightAnswer=A
|RightAnswer=A
|Approved=Yes
|Approved=Yes
}}
}}

Revision as of 18:41, 3 August 2014
Author [[PageAuthor::Serge Korjian, M.D. (Reviewed by Serge Korjian)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pharmacology
Sub Category SubCategory::Cardiology, SubCategory::Vascular
Prompt [[Prompt::The mechanism of action of a novel experimental drug is under investigation. The drug is intended to treat patients with atrial and ventricular arrhythmias who cannot tolerate other therapies. After initial rat testing, the core lab determines that the active molecule acts on the transmembrane proteins that regulate the resting membrane potential of cardiomyocytes. ECG monitoring demonstrates significant, dose-dependent increase in the QT interval in treated rats. Which of the following drugs is likely to be related to the experimental drug being evaluated?]]
Answer A AnswerA::Sotalol
Answer A Explanation AnswerAExp::
Answer B AnswerB::Procainamide
Answer B Explanation AnswerBExp::
Answer C AnswerC::Propafenone
Answer C Explanation AnswerCExp::
Answer D AnswerD::Metoprolol
Answer D Explanation AnswerDExp::
Answer E AnswerE::Mexiletine
Answer E Explanation AnswerEExp::
Right Answer RightAnswer::A
Explanation [[Explanation::

Educational Objective:
References: Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62(1):9-33.]]

Approved Approved::Yes
Keyword
Linked Question Linked::
Order in Linked Questions LinkedOrder::
Retrieved from "https://www.wikidoc.org/index.php?title=WBR0401&oldid=1006326"